CIAM
RLMD icon

Caitong International Asset Management’s Relmada Therapeutics RLMD Stock Holding History

Caitong International Asset Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$251 Buy
+36
New +$170 ﹤0.01% 1838

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Caitong International Asset Management's RLMD Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Relmada Therapeutics (RLMD) in Q1 2026: 36 shares worth $251. The stake represents ﹤0.01% of the portfolio and ranks #1838 among its holdings.

103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Caitong International Asset Management held 36 shares of Relmada Therapeutics worth $251 as of Q1 2026.
  • Relmada Therapeutics was a new Caitong International Asset Management position in Q1 2026.
  • Relmada Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #1838 holding.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.